<DOC>
	<DOCNO>NCT00019500</DOCNO>
	<brief_summary>RATIONALE : Chemoprevention therapy use certain drug try prevent development recurrence cancer . The use raloxifene may effective way prevent breast cancer premenopausal woman . PURPOSE : Phase II trial study effectiveness raloxifene prevent invasive breast cancer premenopausal woman .</brief_summary>
	<brief_title>Raloxifene Preventing Breast Cancer Premenopausal Women</brief_title>
	<detailed_description>OBJECTIVES : - Determine safety tolerability raloxifene premenopausal woman high risk develop invasive breast cancer . - Determine effect raloxifene blood steroid hormone level ( luteinizing hormone , estradiol , progesterone ) carotenoid level menstrual cycle participant . - Determine effect raloxifene endometrium ovaries participant . - Determine effect raloxifene biochemical marker bone metabolism , lipid profile , fibrinogen participant . - Determine effect raloxifene health-related quality life participant . - Determine effect raloxifene bone mineral density spine hip participant . OUTLINE : This open-label study . Participants medically evaluate , follow observation period 1 2 menstrual cycle . After observation period , participant receive oral raloxifene daily 2 year . Quality life assess 1 week prior study drug administration 6 , 12 , 24 36 month study drug administration . Participants follow 1 year . PROJECTED ACCRUAL : A total 41 participant accrue study within 3 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Raloxifene Hydrochloride</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : At risk develop invasive breast cancer virtue 1 follow criterion : Gail model risk equal average 60 year old woman determine use Gail risk assessment model Lobular neoplasia Atypical ductal hyperplasia positive family history breast cancer Ductal carcinoma situ previously treat mastectomy lumpectomy radiation BRCA1 BRCA2 mutationpositive genotyping Family history consistent hereditary cancer syndrome increase breast cancer risk define 1 following : Family 2 breast cancer case one case ovarian cancer diagnose age Family 3 breast cancer case diagnose age 50 Sister pair 2 breast cancer , 2 ovarian cancer , 1 breast 1 ovarian cancer diagnose age 50 Premenopausal Menstrual cycle 2635 day No change menstrual pattern within past 6 month ( irregularity ) FSH level le 20 mIU/mL Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age 23 47 Sex Female Menopausal status Premenopausal Performance status Not specify Life expectancy Not specify Hematopoietic No history bleed disorder Hepatic No history cirrhosis liver SGOT/SGPT great 3 time upper limit normal ( ULN ) Renal Creatinine great 1.7 mg/dL Cardiovascular No history pulmonary embolism deep venous thrombosis Other Not pregnant nursing Negative pregnancy test Fertile participant must use effective nonhormonal contraception ( e.g . barrier method , spermicide , surgical method ) 3 month study No history infertility suspect ovarian etiology recurrent ovarian cysts No allergy raloxifene No dysfunctional uterine bleed No menorrhagia No cervical dysplasia significant uterine pathology require concurrent surgery No medical psychiatric disorder would preclude study participation Normal CA 125 level PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy At least 6 month since prior steroid therapy ( e.g. , tamoxifen , estrogen , DHEA , anabolic steroid , oral contraceptive ) Radiotherapy See Disease Characteristics Surgery See Disease Characteristics No prior hysterectomy</criteria>
	<gender>Female</gender>
	<minimum_age>23 Years</minimum_age>
	<maximum_age>47 Years</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>breast cancer</keyword>
</DOC>